Pfizer Inc's Revenue in the fiscal year 2025 $ 62,579.00 millions
Pfizer Inc's Revenue in the fiscal year 2024 $ 63,627.00 millions
Pfizer Inc's Revenue in the fiscal year 2023 $ 58,496.00 millions
Pfizer Inc's Revenue in the fiscal year 2022 $ 100,330.00 millions
Pfizer Inc's Revenue in the fiscal year 2021 $ 81,288.00 millions
PFE Revenue third quarter 2026 Y/Y Growth Comment
Pfizer Inc reported decrease in Revenue in the third quarter 2026 by -0.43% to $ 16,583.00 millions, from the same quarter in 2025. The decrease in the third quarter 2026 Pfizer Inc's Revenue compares unfavorably to the Company's average Revenue growth of 5.2%.
Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 137 other companies have achieved higher Revenue growth. While Pfizer Inc' s Revenue decline of -0.43% ranks overall at the positon no. 2902 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Pfizer Inc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
145.2 %
1.62 %
-50.98 %
(Apr 04 2021)
PFE's III. Quarter Q/Q Revenue Comment
Pfizer Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 10.3%, to $ 16,583.00 millions, from $15,034.00 millions in the second quarter.
Within Major Pharmaceutical Preparations industry 54 other companies have achieved higher Revenue quarter on quarter growth. While Pfizer Inc's Revenue growth quarter on quarter, overall rank is 818.
Pfizer Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 10.3%, to $ 16,583.00 millions, from $15,034.00 millions in the second quarter.
Within Major Pharmaceutical Preparations industry 54 other companies have achieved higher Revenue quarter on quarter growth. While Pfizer Inc's Revenue growth quarter on quarter, overall rank is 818.
Pfizer Inc's 12 Months Revenue Growth Year on Year
Although Pfizer Inc's Annual Revenue growth year on year were below company's average 3.08% , Revenue announced in the Sep 27 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.34% year on year, from -0.21% in Jun 28 2026.
In the Healthcare sector 316 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2535, from total ranking in previous quarter at 3214.
Although Pfizer Inc's Annual Revenue growth year on year were below company's average 3.08% , Revenue announced in the Sep 27 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.34% year on year, from -0.21% in Jun 28 2026.
In the Healthcare sector 316 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2535, from total ranking in previous quarter at 3214.
About Pfizer Inc Revenue Growth Rates (PFE), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
